Abbott expands influenza test offering
Abbott is rolling out BinaxNOW Influenza A & B Card 2, its latest rapid influenza diagnostic test.
The reformulated test has been granted waived status under the Clinical Laboratory Improvements Amendments by the Food and Drug Administration for use with Abbott's Digival diagnostic reader, formerly Alere reader, for the rapid detection of influenza virus.
The Digival reader accurately reads and interprets BinaxNOW Influenza A & B Card 2 tests in seconds, delivering automated, objective results in a broad range of healthcare settings, the company said.
The combined platform is available for use in hospital laboratories, emergency rooms, physician offices, walk-in clinics and urgent care centers throughout the U.S.
"This flu season, healthcare providers need objective tests that can provide fast, accurate results to determine the best course of care for patients," Abbott senior vice president, rapid diagnostics, Sharon Bracken said. "The BinaxNOW Influenza A & B Card 2 adds to our strong portfolio of rapid flu tests by providing rapid and easy diagnosis, while Digival enhances healthcare providers' confidence in results by reducing user subjectivity."
"The BinaxNOW Influenza A & B Card 2 and Digival platform take the guesswork out of interpreting visually-read tests, empowering our staff to give an accurate influenza diagnosis and put patients on the path to recovery," ProHealth strategic sourcing and procurement manager, Marissa Ciminera said. "We've installed Digival across our practices as it offers significant improvement over the subjective, visually-read tests we have historically used."
The reformulated test has been granted waived status under the Clinical Laboratory Improvements Amendments by the Food and Drug Administration for use with Abbott's Digival diagnostic reader, formerly Alere reader, for the rapid detection of influenza virus.
The Digival reader accurately reads and interprets BinaxNOW Influenza A & B Card 2 tests in seconds, delivering automated, objective results in a broad range of healthcare settings, the company said.
The combined platform is available for use in hospital laboratories, emergency rooms, physician offices, walk-in clinics and urgent care centers throughout the U.S.
"This flu season, healthcare providers need objective tests that can provide fast, accurate results to determine the best course of care for patients," Abbott senior vice president, rapid diagnostics, Sharon Bracken said. "The BinaxNOW Influenza A & B Card 2 adds to our strong portfolio of rapid flu tests by providing rapid and easy diagnosis, while Digival enhances healthcare providers' confidence in results by reducing user subjectivity."
"The BinaxNOW Influenza A & B Card 2 and Digival platform take the guesswork out of interpreting visually-read tests, empowering our staff to give an accurate influenza diagnosis and put patients on the path to recovery," ProHealth strategic sourcing and procurement manager, Marissa Ciminera said. "We've installed Digival across our practices as it offers significant improvement over the subjective, visually-read tests we have historically used."